Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Senderowicz

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasmsE A Sausville, S G Arbuck, R Messmann, et al.
European Journal of Biochemistry|September 21, 2000
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25M Leost, C Schultz, A Link, et al.
Cancer Research|August 12, 1998
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoproteinE Fuse, H Tanii, N Kurata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann, E S Vitetta, D Headlee, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasmsE A Sausville, S G Arbuck, R Messmann, et al.
European Journal of Biochemistry|September 21, 2000
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25M Leost, C Schultz, A Link, et al.
Cancer Research|August 12, 1998
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoproteinE Fuse, H Tanii, N Kurata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann, E S Vitetta, D Headlee, et al.
Pageof 4